BRPI0715318A2 - mÉtodo para reduzir a pressço itraocular e mÉtodo para assegurara a liberaÇço de uma composiÇço terapÊutica para reduzir a pressço intraocular - Google Patents

mÉtodo para reduzir a pressço itraocular e mÉtodo para assegurara a liberaÇço de uma composiÇço terapÊutica para reduzir a pressço intraocular Download PDF

Info

Publication number
BRPI0715318A2
BRPI0715318A2 BRPI0715318-0A BRPI0715318A BRPI0715318A2 BR PI0715318 A2 BRPI0715318 A2 BR PI0715318A2 BR PI0715318 A BRPI0715318 A BR PI0715318A BR PI0715318 A2 BRPI0715318 A2 BR PI0715318A2
Authority
BR
Brazil
Prior art keywords
mrs
eye
adenosine
intraocular pressure
subtype
Prior art date
Application number
BRPI0715318-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Marcel Y Avila
Richard Stone
Civan M Mortimer
Kenneth A Jacobson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BRPI0715318A2 publication Critical patent/BRPI0715318A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BRPI0715318-0A 2006-10-06 2007-10-05 mÉtodo para reduzir a pressço itraocular e mÉtodo para assegurara a liberaÇço de uma composiÇço terapÊutica para reduzir a pressço intraocular BRPI0715318A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85017506P 2006-10-06 2006-10-06
US60/850,175 2006-10-06
PCT/US2007/021409 WO2008045330A2 (en) 2006-10-06 2007-10-05 Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure

Publications (1)

Publication Number Publication Date
BRPI0715318A2 true BRPI0715318A2 (pt) 2013-07-16

Family

ID=39283379

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715318-0A BRPI0715318A2 (pt) 2006-10-06 2007-10-05 mÉtodo para reduzir a pressço itraocular e mÉtodo para assegurara a liberaÇço de uma composiÇço terapÊutica para reduzir a pressço intraocular

Country Status (8)

Country Link
US (1) US20090258836A1 (cg-RX-API-DMAC7.html)
EP (1) EP2076267A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010505848A (cg-RX-API-DMAC7.html)
AU (1) AU2007307157A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0715318A2 (cg-RX-API-DMAC7.html)
CA (1) CA2665616A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009003750A (cg-RX-API-DMAC7.html)
WO (1) WO2008045330A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) * 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
US10196396B2 (en) 2016-01-14 2019-02-05 Handok Inc. Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
KR101805400B1 (ko) * 2017-03-21 2017-12-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
KR102007640B1 (ko) * 2017-11-29 2019-08-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물
US11395597B2 (en) * 2018-06-26 2022-07-26 General Electric Company System and method for evaluating blood flow in a vessel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
EP1096975B1 (en) * 1998-07-16 2005-03-16 The Trustees Of The University Of Pennsylvania Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
EP2076267A4 (en) 2013-07-31
US20090258836A1 (en) 2009-10-15
AU2007307157A1 (en) 2008-04-17
WO2008045330A2 (en) 2008-04-17
MX2009003750A (es) 2009-06-18
JP2010505848A (ja) 2010-02-25
EP2076267A2 (en) 2009-07-08
WO2008045330A3 (en) 2008-06-26
CA2665616A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
US20090258836A1 (en) Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
Swerdlow et al. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat.
Koseki et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure
US6528516B1 (en) Methods for reducing intraocular pressure using A3 adenosine receptor antagonists
US5798380A (en) Cytoskeletal active agents for glaucoma therapy
Sears Regulation of aqueous flow by the adenylate cyclase receptor complex in the ciliary epithelium
US12102640B2 (en) Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
Wang et al. Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species
Marino et al. Binge ethanol drinking associated with sex-dependent plasticity of neurons in the insula that project to the bed nucleus of the stria terminalis
CA2965129C (en) Method of treating ocular conditions using varenicline
Donnenfeld et al. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug
NO343597B1 (no) Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon
US20060166972A1 (en) Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
TW201605443A (zh) 治療x染色體脆折症及相關病症的方法
US20200179357A1 (en) Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation
KR20200138197A (ko) 중독 및 관련 장애를 치료하기 위한 화합물 및 방법
Stumpff et al. Characterization of maxi-K-channels in bovine trabecular meshwork and their activation by cyclic guanosine monophosphate.
Liu et al. Atypical antipsychotics block the excitatory effects of serotonin in septohippocampal neurons in the rat
WO1990006123A1 (en) Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
Brubaker et al. Topical forskolin (colforsin) and aqueous flow in humans
TW202237076A (zh) 鞏膜薄化治療用點眼劑及鞏膜薄化治療劑之篩選方法
Baizman et al. Pharmacologic profile of fezolamine fumarate: a nontricyclic antidepressant in animal models.
US20090054412A1 (en) Treatment of Sleep Disorders
Zhdanova et al. Effects of melatonin ingestion on cAMP and cGMP levels in human plasma
Wang et al. Barrier qualities of the mouse eye to topically applied drugs

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.